Lin He is the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research and Professor of Cell Biology and Physiology at the University of California, Berkeley. His laboratory focuses on understanding the biological functions of non-coding RNAs in development and disease, with particular emphasis on microRNAs (miRNAs) in cancer, stem cell biology, and developmental processes. He developed the CRISPR-EZ method for highly efficient mouse genome editing, significantly advancing genetic research. Research interests include miRNAs' roles in tumor progression, metastasis, and pluripotency regulation in stem cells. His work bridges mouse genetics, genomics, and molecular biology to uncover mechanisms governing non-coding RNA functions. Current projects address miRNAs in oncogenesis, stem cell fate determination, and the interplay between non-coding RNAs and retrotransposons in development. Key contributions include identifying miRNA networks in cancer pathways, demonstrating miRNA requirements for ciliogenesis and lung development, and advancing CRISPR-based genome editing techniques. His interdisciplinary approach integrates genetic, genomic, and cellular tools to explore fundamental questions in biology and medicine. Lab website: helabucb.org CRISPR-EZ technology enables 100% genome editing efficiency in mouse zygotes Pioneering studies on miRNA regulation of PTEN, p53, and oncogene pathways
Hang Lu is an Associate Professor in the Department of Communication and Media at the University of Michigan's College of Literature, Science, and the Arts. He specializes in science, health, environmental, and risk communication (ComSHER), with a focus on media psychology. His research explores audience responses to media messages about sensitive topics and strategies to enhance message effectiveness. Lu holds a Ph.D. in Communication from Cornell University (2018), along with advanced degrees from Cornell, Marquette University, and Central South University in China. He directs the Media and Risk (MaR) Lab and previously served as a postdoctoral fellow at the Annenberg Public Policy Center. His research spans four main areas: 1) emotion dynamics in media responses, 2) predictors of information behaviors, 3) media effects on stigmatization, and 4) AI applications in sensitive domains. He has published in journals like Journal of Communication , Risk Analysis , and Public Understanding of Science , earning multiple top paper awards. As Vice Chair of the Environmental Communication Division at the International Communication Association, Lu contributes to interdisciplinary dialogue. His work addresses critical societal issues such as climate change communication, vaccination hesitancy, and emerging technology ethics.
Dr. Christina Leslie is a Research Professor and Member of the Computational & Systems Biology Program at Memorial Sloan Kettering Cancer Center (MSK). She leads an active research laboratory focused on developing computational approaches to understand complex biological systems. Dr. Leslie earned her PhD from the University of California, Berkeley and has established herself as a leading computational biologist in cancer research and immunology. Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center Gerstner Sloan Kettering Graduate School of Biomedical Sciences Dr. Leslie's research focuses on developing novel computational methods to study cellular biological systems from a global and data-driven perspective. Her lab exploits diverse high-throughput functional and genomic data to understand molecular networks underlying fundamental cellular processes, including transcription regulation, pre-mRNA processing, signaling, and post-transcriptional gene silencing. Her algorithmic methods draw heavily on machine learning to build accurate predictive models from noisy and high-dimensional biological data. Key areas of interest include modeling cell-type specific transcriptional programs and dissecting co- and post-transcriptional regulation, particularly microRNA-mediated gene regulation. Analysis of Dr. Leslie's publication record over the last five years reveals a strong focus on computational approaches to cancer genomics, immunology, and epigenetics. Her work bridges multiple disciplines, with a particular emphasis on developing machine learning methods to interpret complex biological data. The publications demonstrate increasing sophistication in integrating multiple data types (genomic, transcriptomic, epigenomic) to understand cancer biology and immune responses. Recent work shows a growing emphasis on single-cell technologies and spatial analysis of tumor microenvironments. Introduction of string kernel methodology for SVM classification of biological sequences Development of algorithms for predictive modeling of gene regulation First systems-level analyses of competition between microRNAs and between target transcripts Dr. Leslie actively mentors numerous graduate students and research associates, with current lab members including Vianne Gao, Alireza Karbalaghareh, Erik Ladewig, and several others. Her lab has received significant research funding to support their work on computational approaches to cancer biology and immunology. The Leslie Lab maintains close collaborations with multiple experimental groups at MSK, facilitating the translation of computational insights into biological understanding. The Leslie Lab operates within the Computational & Systems Biology Program at MSK, with strong ties to both the research and clinical missions of the institution. The lab maintains state-of-the-art computational infrastructure for analyzing large-scale genomic and proteomic datasets and collaborates extensively with wet-lab researchers to validate computational predictions experimentally.
Dr. Vadim Backman is the Sachs Family Professor of Biomedical Engineering and Medicine at Northwestern University's McCormick School of Engineering and Applied Sciences and Feinberg School of Medicine. He holds additional roles as Professor of Medicine (Hematology/Oncology) and Biochemistry and Molecular Genetics, Associate Director of Research Technology and Infrastructure at the Robert H. Lurie Comprehensive Cancer Center, and Director of the Center for Physical Genomics and Engineering. He earned his Ph.D. in Medical Engineering from Harvard-MIT and M.S./B.S. in Physics from St. Petersburg Polytechnic Institute. His research focuses on physical and biological science intersections, developing nanoscale imaging and computational technologies to study chromatin dynamics and their role in disease. Key areas include cancer diagnostics/therapeutics, chromatin engineering, and genome nanoimaging. Dr. Backman has published over 230 papers, holds 20+ patents, and leads large-scale projects like NCI Bioengineering Research Partnerships. Education: Ph.D. (Harvard-MIT), M.S. (MIT), M.S./B.S. (St. Petersburg Polytechnic Institute) Affiliations: PhD Programs in Applied Physics and Interdisciplinary Biological Sciences Research emphasizes chromatin's role in disease, with clinical translation for diagnostics and therapy. His lab develops technologies like nano-CHIA and ChromSTEM, advancing understanding of genomic organization and epigenetic regulation. Awards include the Cozzarelli Prize and MIT Technology Review's Top 100 Innovators. Awards: Cozzarelli Prize (2017), AIMBE Fellowship (2009), NSF CAREER Award (2003) Grants and collaborations include managing multi-investigator projects and co-founding biotech companies. Courses taught: BME 302 (Quantitative Systems Physiology), BME 429 (Advanced Physical and Applied Optics).
Michael Levin is a Vannevar Bush Professor and Distinguished Professor at Tufts University, affiliated with the School of Arts and Sciences (Department of Biology) and School of Engineering (Biomedical Engineering). His research focuses on bioelectricity, developmental biology, and collective intelligence. He leads the Allen Discovery Center and the Tufts Center for Developmental and Regenerative Biology. Education: PhD in Genetics from Harvard Medical School (1996); BS in Computer Science and Biology from Tufts University (1992). Research Interests: Integrates developmental biology, computer science, and cognitive science to study morphogenesis, regeneration, and cancer. Explores bioelectric signaling, synthetic organisms, and AI-driven discovery. Key areas include regenerative medicine, cancer reprogramming, and collective intelligence in biological systems. Publications: Over 600 articles, with recent work on xenobots, neuroevolution, and bioelectric therapies. Themes include bioelectric control of form, AI in biology, and collective intelligence. Awards: INNS Donald O. Hebb Award, AAAS Fellow, and Vox Future Perfect 50 List recognition. Frequently invited to speak at conferences on biology, AI, and consciousness. Advising & Labs: Mentored numerous postdocs and students, including pioneers in bioelectricity and synthetic biology. Lab focuses on interdisciplinary approaches to biological pattern formation and regeneration.
Pablo Perez-Pinera is an Associate Professor in Biomedical and Translational Sciences at the Carle Illinois College of Medicine, University of Illinois. He leads the Genome Engineering and Transcriptional Regulation Laboratory, focusing on developing gene editing technologies for treating neurodegenerative and neuromuscular diseases. His research integrates cutting-edge genome engineering tools with innovative delivery systems to address previously incurable conditions. Dr. Perez-Pinera's research interests center on developing CRISPR-based genome editing technologies for therapeutic applications. His laboratory specializes in base editing approaches for exon skipping, particularly targeting diseases like Duchenne muscular dystrophy, Huntington's disease, Parkinson's disease, Alzheimer's disease, and ALS. His team develops novel delivery systems using AAV vectors to enable precise in vivo genome editing, with a particular focus on neurological and muscular disorders. The lab's work bridges fundamental molecular biology with translational applications, aiming to move promising technologies from bench to bedside. His laboratory has made significant contributions to the field of therapeutic genome editing, particularly in developing the SPLICER platform for efficient exon skipping through simultaneous splice site editing. His publications demonstrate expertise in base editing for neurodegenerative diseases, with multiple first-author and corresponding author papers in high-impact journals. His research has been supported by several NIH grants including R01 GM131272, UL1 TR001422, R01 GM141296, among others. Dr. Perez-Pinera actively mentors a diverse team of researchers including postdoctoral fellows, graduate students, and undergraduates. His laboratory includes researchers such as Devyani Swami (Postdoctoral Fellow), Michael Gapinske, Jackson Winter, Shraddha Shirguppe, Angelo Miskalis, and others who contribute to various aspects of genome engineering research. His grant funding supports both basic research on genome editing mechanisms and translational work toward therapeutic applications. The Genome Engineering and Transcriptional Regulation Laboratory maintains state-of-the-art facilities for molecular biology, cell culture, and in vivo studies. The team collaborates extensively with clinicians and researchers across the University of Illinois campus to translate genome editing discoveries into potential therapies for patients suffering from neurodegenerative and neuromuscular conditions.
Dr. Angelika Rambold is a Group Leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, heading the Laboratory for Metabolic Organelle Networks in Immunology within the Department of Developmental Immunology. Previously affiliated with the University of Münster's Center for Molecular Biology of Inflammation (ZMBE) and Institute of Medical Biochemistry until January 2025, she investigates how intracellular organelle networks regulate immune cell function during inflammation, infection, and metabolic stress. Her research centers on dynamic interactions between mitochondria, lysosomes, lipid droplets, and autophagosomes during cellular adaptation to nutrient deprivation and pathogen challenge. Key interests include organelle communication mechanisms in immune cell activation, metabolic reprogramming in T cells and macrophages, and how defects in organelle networks drive primary immunodeficiencies like Chediak-Higashi syndrome. She employs advanced live-cell microscopy, super-resolution imaging, metabolomics, and single-cell transcriptomics to dissect these processes in primary immune cells and human disease models. Analysis of her publication record reveals consistent focus on mitochondrial dynamics as a central regulator of immune cell metabolism and fate determination. Landmark studies demonstrate TFEB-mediated itaconate synthesis for bacterial control in macrophages and coordinated organelle network responses during starvation, establishing critical links between organelle communication, immunometabolism, and disease pathogenesis across multiple immune cell types. Dr. Rambold serves as a supervisor in the Cells in Motion International Max Planck Research School (CiM-IMPRS) Graduate Programme, mentoring PhD students in interdisciplinary research. Her laboratory maintains active collaboration with the Center for Chronic Immunodeficiency (CCI) at the University of Freiburg to translate basic findings on organelle-mediated immune defects into clinical insights for patient-oriented research.
Amy Catherine Rowat is a full Professor in the Department of Integrative Biology and Physiology at UCLA's College of Letters and Science. She directs an interdisciplinary research program that integrates mechanobiology, microfluidics, cancer biophysics and food engineering to understand how physical forces shape cell behavior and to develop sustainable biotechnologies. Education & Affiliations: Professor, Department of Integrative Biology and Physiology, UCLA Member, UCLA College of Letters and Science Research Interests: Rowat's group deciphers how mechanical properties of cells and their nuclei influence disease progression and therapeutic response. Using high-throughput microfluidic deformability cytometry, her team discovered that cancer cells become stiffer and more invasive upon β-adrenergic signaling, linking stress hormones to metastatic potential. Parallel efforts focus on nuclear envelope mechanics, showing that histone H1.0 and transient nuclear deformation modulate chromatin structure and cell reprogramming. Beyond biomedicine, Rowat pioneers biophysical approaches for sustainable food production. She engineers edible scaffolds and emulsion-templated microcarriers to culture meat at scale, demonstrating spontaneous fusion of adipogenic and myogenic microtissues into marbled steak-like constructs. Recent Article Trends (2020-2025): Her latest publications reveal a cohesive trajectory: coupling mechanobiology to epigenetic regulation (viscoelastic matrix enhances chromatin remodeling), advancing single-cell mechanical phenotyping (optomagnetic arrays, high-throughput screens), translating findings to cancer therapy (β-blockers to sensitize chemotherapy) and expanding engineered foods (scalable cultured-meat bioprocessing). Funding & Awards: NIH R21 CA245667 (PI) – Repurposing beta-blockers to improve chemotherapy response (2021-2023) Laboratory & Teams: Rowat leads an active research laboratory at UCLA that trains graduate students and postdocs at the intersection of physics, engineering and biology. The lab maintains collaborations across UCLA Engineering, Jonsson Comprehensive Cancer Center, and external partners in food science and biotechnology companies.
Song Li is a Chancellor's Professor in the Department of Bioengineering at the University of California, Los Angeles (UCLA) and serves as Associate Dean for Graduate and Professional Education. His research intersects engineering, biology, and medicine to advance cell engineering, mechanobiology, and immunoengineering. Education: B.S. and M.S. from Peking University; Ph.D. in Bioengineering from University of California, San Diego. Li Lab focuses on mechanotransduction, cell reprogramming for regenerative medicine, and immunoengineering. Research emphasizes translating discoveries into biomedical applications through multidisciplinary collaborations. The lab's recent work in Nature Materials explores how nuclear deformation impacts epigenetic states and cell reprogramming. Publications reflect expertise in mechanobiology, regenerative medicine, and bioengineering technologies. Scientific Awards: Chancellor's Professorship, IAMBE Fellow, Biomedical Engineering Society Fellow, AIMBE Fellow, and UC Systemwide Bioengineering Symposium keynote. Li Lab fosters innovation in cell engineering and immunoengineering, with grants including coronavirus vaccine booster research. The lab promotes diversity, equity, and inclusion in collaborative biomedical discovery.
Sai Reddy is an Associate Professor of Systems and Synthetic Immunology at ETH Zurich's Department of Biosystems Science and Engineering (D-BSSE) in Basel, Switzerland, where he leads the Laboratory for Systems and Synthetic Immunology. Since September 2018, he has served as Vice Director of the Botnar Research Centre for Child Health (BRCCH), driving child health innovation through interdisciplinary research. Education: Bachelor of Science (Biomedical Engineering) from Northwestern University (2003) Master of Science (Biomedical Engineering) from Northwestern University (2004) Ph.D. (Bioengineering and Biotechnology) from École Polytechnique Fédérale de Lausanne (EPFL) (2008), supervised by Prof. Melody Swartz and Prof. Jeffrey Hubbell Post-doctoral fellowship under Prof. George Georgiou at the University of Texas, Austin (2008) His research pioneers the integration of computational modeling and cellular engineering to decode immune complexity. Systems Immunology employs quantitative measurements and machine learning to analyze adaptive immunity through antibody repertoire sequencing, while Synthetic Immunology reprograms immune cells via molecular engineering for cellular immunotherapy and directed evolution applications. Both fields converge on immunogenome manipulation to advance therapeutic design. Scientific Awards: KPMG tomorrow’s market award (2007) for nanoparticle vaccine technology As principal investigator, Prof. Reddy mentors graduate researchers in his laboratory; no specific advisees or grant awards are detailed in the text. His leadership at BRCCH amplifies translational impact on child health, though operational grant mechanisms remain undisclosed. The Laboratory for Systems and Synthetic Immunology operates from ETH Zurich's Basel campus at Klingelbergstrasse 48, Switzerland, focusing on high-throughput sequencing and synthetic biology methods to engineer immune responses.
Kunihiko Kaneko is a Professor at the Niels Bohr Institute, University of Copenhagen, with a distinguished career in theoretical biophysics and complex systems. He received his PhD and MSc in Physics from the University of Tokyo, and has held leadership roles at the Universal Biology Institute and Center for Complex Systems Biology. PhD Physics, 1984 - University of Tokyo MSc Physics, 1981 - University of Tokyo His research spans five primary areas: Universal Biology, Evolutionary Constraints, Ecosystem Dynamics, Neural Cognition, and Universal Anthropology. He has published extensively on multi-level consistency principles, dimensional reduction in biological systems, and reciprocity between robustness and plasticity across scales. Recent publications show strong focus on microbial ecosystems (2025), evolutionary game theory (2025), neural modular architectures (2024), and dimensional reduction in cellular systems (2024). His work bridges physics and biology through dynamical systems theory applied to diverse phenomena from protocells to human societies.
Professor Faye Rogers serves as Professor of Therapeutic Radiology at Yale University School of Medicine, holding multiple leadership positions including Associate Cancer Center Director for YCC Collaborative Excellence, Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her work bridges radiation oncology, DNA repair mechanisms, and cancer therapeutics within Yale's comprehensive cancer research ecosystem. PhD from University of Maryland at Baltimore (1998) Postdoctoral Fellow at Yale School of Medicine Dr. Rogers' research focuses on the intersection of DNA repair mechanisms and cancer therapeutics, with particular expertise in triplex DNA structures, genomic instability, and targeted cancer therapies. Her work explores how DNA damage responses can be leveraged for therapeutic benefit, especially in breast neoplasms and other malignancies. Through her leadership in the DNA Damage and Genome Integrity program, she investigates novel approaches to disrupt cancer cell survival mechanisms while sparing healthy tissue. Her research has significant implications for radiation oncology, particularly in developing more precise and effective radiation-based treatments. Analysis of Dr. Rogers' publication record reveals a consistent trajectory in DNA repair mechanisms and cancer therapeutics, with increasing focus on translational applications. Her work demonstrates expertise in triplex DNA structures, RAD51 inhibition, and synthetic lethality approaches. Recent publications show a shift toward more clinically applicable research, particularly in targeting DNA repair pathways in specific cancer subtypes like IDH1-mutant cancers and PTEN-deficient glioblastomas. Her collaborative work with Peter Glazer and others demonstrates strong interdisciplinary connections between radiation oncology, molecular biology, and drug development. Leadership in Diversity, Equity & Inclusion Award (Yale School of Medicine, 2022) Translational Science Research Prize (Yale Cancer Center, 2022) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a pivotal role in mentoring the next generation of physician-scientists and supporting underrepresented minorities in biomedical research. Her leadership in collaborative excellence initiatives demonstrates commitment to fostering interdisciplinary research teams across Yale's scientific ecosystem. Through the YCC Collaborative Excellence program, she has secured significant funding for innovative cancer research that bridges basic science and clinical applications, particularly in the areas of DNA repair targeting and radiation oncology. Dr. Rogers leads research within Yale's Therapeutic Radiology department, with strong connections to the Radiobiology program and the Yale Cancer Center. Her work is integrated with the Program in Translational Biomedicine and the Yale Combined Program in the Biological and Biomedical Sciences. Through the BioMed Amgen Scholars Program, she provides critical research opportunities for undergraduate students, particularly those from underrepresented backgrounds, fostering talent in DNA repair research and cancer therapeutics.
Kara McKinley is an Assistant Professor of Stem Cell and Regenerative Biology at Harvard University , joining the department in 2021. She is a Principal Faculty member at the Harvard Stem Cell Institute , an Associate member of the Broad Institute of MIT and Harvard , and a Freeman Hrabowski Scholar at the Howard Hughes Medical Institute . Her research focuses on the regenerative capacity of the human uterus , particularly the endometrium, which undergoes ~400 cycles of tissue remodeling, shedding, and repair during the reproductive lifespan. Using rodent models , genetic, molecular, and live microscopy tools, her lab investigates cellular and molecular mechanisms of regeneration, defects leading to diseases like endometriosis, and applications in regenerative medicine . Her work also explores cell division , centromere biology , and CRISPR genome engineering . Current research trends in her publications include epithelial zonation in the small intestine , mechanisms of endometrial regeneration , macropinocytosis in Hydra , and academic mentorship strategies . Her studies span cellular biomechanics , mitotic regulation , and translational approaches for tissue repair. NIH Director’s New Innovator Award (terminated in 2025 litigation with federal government) Freeman Hrabowski Scholar (Broad Institute) Kara mentors Harvard undergraduates, graduate students, and postdoctoral fellows through rotations and research opportunities. Her lab is based at Harvard’s Bauer 306 and advocates for gender equity in life sciences faculty via the Leading Edge initiative. Funding includes a now-terminated NIH New Innovator grant aimed at menstrual health research.
Prof. Dr. Soeren Lienkamp is an Assistant Professor at the Institute of Anatomy , Faculty of Medicine , University of Zurich . His work bridges digital education and genetic research , focusing on enhancing medical teaching through innovative formats. Research Interests : Genetics, developmental biology, kidney disease modeling, CRISPR applications, digital medical education, and advanced microscopy. Methodologies : Combines Xenopus tropicalis models, deep learning , and bioengineering to study genetic kidney disorders and improve diagnostic tools. Publication Trends : His recent articles highlight predictable genome editing , 3D imaging technologies , and mechanistic insights into kidney and eye development. Earlier works focus on ciliary function , Wnt signaling , and metabolic stress in renal cells.
Wen Xue is a Professor at UMass Chan Medical School, affiliated with the RNA Therapeutics Institute within the T.H. Chan School of Medicine. She holds multiple additional roles across departments such as the Program in Molecular Medicine, Cancer Biology, and Biochemistry and Molecular Biotechnology at the Morningside Graduate School of Biomedical Sciences. Her research focuses on developing genetic models for liver and lung cancer using CRISPR/Cas9 and RNAi tools. Key areas include CRISPR-mediated genome editing for cancer gene discovery, KRAS inhibition mechanisms, and miRNA networks in lung cancer. She has secured grants from NIH, American Cancer Society, and others. Awards include the NIH Director’s New Innovator Award and Lung Cancer Research Foundation grants. Her lab actively recruits postdoctoral researchers and offers rotation projects in CRISPR technology and cancer biology. Education: B.S. and M.S. in Biochemistry from Nanjing University; Ph.D. in Biochemistry from State University of New York, Stony Brook. Research Interests: Wen Xue’s lab employs CRISPR tools to accelerate cancer gene validation and therapeutic target identification. Projects include: CRISPR-based liver cancer gene correction and oncogene deletion studies. Investigating KRAS inhibition resistance via RNAi and CRISPR in lung cancer models. Characterizing miRNA networks using TCGA data to identify therapeutic miRNA candidates. Her work bridges functional genomics with precision medicine, emphasizing in vivo and in vitro platforms. Publications: Over 100 peer-reviewed articles, including high-impact studies on CRISPR applications in gene therapy and cancer modeling. Recent work explores prime editing, base editing, and viral/non-viral delivery systems for lung diseases. Grants & Awards: NIH grants (P01HL131471, DP2HL137167), American Cancer Society (RSG-16-093), and industry partnerships like the Cystic Fibrosis Foundation. Collaborations include projects on CFTR mutation repair and AAV vector development. Labs/Teams: Xue Lab focuses on cancer genetics and gene editing, with interdisciplinary collaborations in molecular medicine and bioengineering. Ongoing projects aim to translate CRISPR-based therapies into clinical applications.
